CTLA4 and neoplasm: Antibodies targeting immune checkpoint inhibitors such as programmed cell death-1 (PD-1) its ligand (PD-L1), or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have greatly contributed to advances in cancer treatment in diverse tumour types (1–4).